
QSAM Biosciences, Inc.
OTC:QSAM
6.1 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | QSAM Biosciences, Inc. |
Symbool | QSAM |
Munteenheid | USD |
Prijs | 7 |
Beurswaarde | 23,015,580 |
Dividendpercentage | 0% |
52-weken bereik | 3.51 - 7.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Douglas R. Baum |
Website | https://qsambio.com |
An error occurred while fetching data.
Over QSAM Biosciences, Inc.
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)